EU Project Findings To ‘Instil Confidence’ In Using Patient Preference Studies
Executive Summary
The European Medicines Agency’s endorsement of a framework that explains how medical device and drug sponsors can use patient preference studies to answer their research questions could help increase confidence in the conduct and acceptability of such studies.
You may also be interested in...
EMA Consults On Proposed Framework For Patient Preference Studies
The EMA is inviting feedback on its plans to ratify, with some caveats, a new framework on how to use patient preferences as input in medical product decision-making. The framework was developed under the EU’s public-private Innovative Medicines Initiative.
BioMarin’s Hemophilia Gene Therapy Among Nine Products On Track For EU-Wide Approval
Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.
EMA Gives Oncopeptides’ Multiple Myeloma Drug The Thumbs Up; Keeps US FDA In Loop
With Pepaxti now on track for pan-EU marketing approval to treat patients with triple class refractory multiple myeloma, Oncopeptides is in talks with the Food and Drug Administration to achieve a clear path forward for the drug in the US where it has experienced difficulties despite being granted an accelerated approval.